Point72 Asia Singapore Pte. Ltd. Has $122,000 Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Point72 Asia Singapore Pte. Ltd. grew its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 749.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,625 shares of the company’s stock after purchasing an additional 18,197 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in MiMedx Group were worth $122,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in MDXG. Harbor Capital Advisors Inc. boosted its holdings in MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after acquiring an additional 770,744 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of MiMedx Group by 339.9% in the 2nd quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock worth $6,164,000 after purchasing an additional 687,267 shares in the last quarter. Dimensional Fund Advisors LP grew its position in MiMedx Group by 47.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after purchasing an additional 413,443 shares during the period. Paradigm Capital Management Inc. NY increased its stake in MiMedx Group by 6.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after purchasing an additional 258,700 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in MiMedx Group during the second quarter worth $988,000. Institutional investors own 79.15% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Trading Down 1.3 %

NASDAQ MDXG opened at $9.47 on Friday. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The business has a fifty day simple moving average of $7.12 and a 200 day simple moving average of $6.93. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $9.68. The firm has a market capitalization of $1.39 billion, a P/E ratio of 17.22 and a beta of 1.98.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.